Hirofumi Mukai

Abemaciclib plus endocrine therapy in chemotherapy-treated patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer

Kazutaka Narui, Kana Miyahara, Yukari Uemura, Akimitsu Yamada et autres

jp (code pays fourni par la source)

Quality of life with palbociclib plus tamoxifen in hormone receptor-positive, HER2-negative advanced breast cancer: results from PATHWAY, an Asian international, double-blind, randomized phase 3 trial

Takashi Yamanaka, J K Sohn, Kazuki Sudo, Hirofumi Mukai et autres

BACKGROUND: In the Asian international PATHWAY trial, palbociclib-tamoxifen demonstrated improved progression-free survival compared with placebo-tamoxifen in patients with HR+/HER2- locally advanced or metastatic breast cancer (ABC). This analysis compared quality of life (QoL) between treatment arms. METHODS: Pre/peri or postmenopausal women with …

jp, kr, tw, sg, us (code pays fourni par la source)

Palbociclib plus tamoxifen ± goserelin in women with hormone receptor (HR)-positive, HER2-negative advanced breast cancer (BC): PATHWAY, an Asian international double-blind randomized phase 3 trial—Final overall survival (OS) analysis.

Yen-Shen Lu, Emi Noguchi, Takashi Yamanaka, Hirofumi Mukai et autres

LBA1018 Background: In Asia, BC incidence is increasing and peaks before menopause; tamoxifen is commonly used for pre/perimenopausal BC. However, tamoxifen was not approved for use in combination with CDK4/6 inhibitors in many countries. PATHWAY previously showed significantly improved progression-free survival (PFS) …

tw, jp, kr, sg (code pays fourni par la source)

Real-world data for a CDK4/6 inhibitor, palbociclib, as 1st- or 2nd-line therapy in HR+/HER2− metastatic breast cancer: a multicenter prospective cohort study

Takashi Ishikawa, Yukari Uemura, Hirohito Seki, Masahiro Kitada et autres

BACKGROUND: Palbociclib (PAL), the first CDK4/6 inhibitor approved for breast cancer, improves progression-free survival (PFS) in hormone receptor-positive (HR+)/HER2-negative (HER2-) metastatic breast cancer (MBC) when added to an aromatase inhibitor or fulvestrant, but also increases toxicity compared to endocrine therapy alone. Use …

jp (code pays fourni par la source)

Real-world uptake of gBRCA testing as a companion diagnostic for olaparib in patients with high-risk HER2-negative early breast cancer in Japan: a cross-sectional multicenter study (BRCAwareness)

Tomoe Taji, Yukari Uemura, Yuri Kimura, Noriko Maeda et autres

BACKGROUND: Adjuvant olaparib significantly improves invasive disease-free and overall survival in high-risk human epidermal growth factor receptor 2 (HER2)-negative, early breast cancer patients carrying germline breast cancer susceptibility gene 1/2 (gBRCA) pathogenic variants (PVs). Timely gBRCA testing as a companion diagnostic for …

jp (code pays fourni par la source)

Effects of ovarian ablation or suppression on breast cancer recurrence and survival: patient-level meta-analysis of 15 000 women in 23 randomised trials

Rosie Bradley, Jeremy Braybrooke, Mike J Clarke, Robert K. Hills et autres

BACKGROUND: For premenopausal women with oestrogen receptor (ER)-positive early breast cancer, the additional protective effect of ovarian function suppression (OFS, by ablation or drugs) may depend on menopausal status after any chemotherapy, and tamoxifen usage. We assess the effects of OFS on …